FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3109883399> ?p ?o ?g. }

• W3109883399 endingPage "374" @default.
• W3109883399 startingPage "368" @default.
• W3109883399 abstract "•In patients with curatively D2-resected, stage II/III, node-positive GC, adjuvant SOX or SOXRT was effective in prolonging DFS, when compared with S-1 monotherapy.•The addition of radiotherapy to chemotherapy did not significantly reduce the rate of recurrence after D2 gastrectomy.•DFS between patients treated with adjuvant chemotherapy and chemoradiotherapy was similar across all subgroups, including Lauren classification. BackgroundAdjuvant chemotherapy and chemoradiotherapy are some of the standards of care for gastric cancer (GC). The Adjuvant chemoRadioTherapy In Stomach Tumors (ARTIST) 2 trial compares two adjuvant chemotherapy regimens and chemoradiotherapy in patients with D2-resected, stage II or III, node-positive GC.Patients and methodsThe ARTIST 2 compared, in a 1:1:1 ratio, three adjuvant regimens: oral S-1 (40-60 mg twice daily 4 weeks on/2 weeks off) for 1 year, S-1 (2 weeks on/1 week off) plus oxaliplatin 130 mg/m2 every 3 weeks (SOX) for 6 months, and SOX plus chemoradiotherapy 45 Gy (SOXRT). Randomization was stratified according to surgery type (total or subtotal gastrectomy), pathologic stage (II or III), and Lauren histologic classification (diffuse or intestinal/mixed). The primary endpoint was disease-free survival (DFS) at 3 years; a reduction of 33% in the hazard ratio (HR) for DFS with SOX or SOXRT, when compared with S-1, was considered clinically meaningful. The trial is registered at clinicaltrials.gov (NCT0176146).ResultsA total of 546 patients were recruited between February 2013 and January 2018 with 182, 181, and 183 patients in the S-1, SOX, and SOXRT arms, respectively. Median follow-up period was 47 months, with 178 DFS events observed. Estimated 3-year DFS rates were 64.8%, 74.3%, and 72.8% in the S-1, SOX, and SOXRT arms, respectively. HR for DFS in the control arm (S-1) was shorter than that in the SOX and SOXRT arms: S-1 versus SOX, 0.692 (P = 0.042) and S-1 versus SOXRT, 0.724 (P = 0.074). No difference in DFS was found between SOX and SOXRT (HR 0.971; P = 0.879). Adverse events were as anticipated in each arm, and were generally well-tolerated and manageable.ConclusionsIn patients with curatively D2-resected, stage II/III, node-positive GC, adjuvant SOX or SOXRT was effective in prolonging DFS, when compared with S-1 monotherapy. The addition of radiotherapy to SOX did not significantly reduce the rate of recurrence after D2 gastrectomy. Adjuvant chemotherapy and chemoradiotherapy are some of the standards of care for gastric cancer (GC). The Adjuvant chemoRadioTherapy In Stomach Tumors (ARTIST) 2 trial compares two adjuvant chemotherapy regimens and chemoradiotherapy in patients with D2-resected, stage II or III, node-positive GC. The ARTIST 2 compared, in a 1:1:1 ratio, three adjuvant regimens: oral S-1 (40-60 mg twice daily 4 weeks on/2 weeks off) for 1 year, S-1 (2 weeks on/1 week off) plus oxaliplatin 130 mg/m2 every 3 weeks (SOX) for 6 months, and SOX plus chemoradiotherapy 45 Gy (SOXRT). Randomization was stratified according to surgery type (total or subtotal gastrectomy), pathologic stage (II or III), and Lauren histologic classification (diffuse or intestinal/mixed). The primary endpoint was disease-free survival (DFS) at 3 years; a reduction of 33% in the hazard ratio (HR) for DFS with SOX or SOXRT, when compared with S-1, was considered clinically meaningful. The trial is registered at clinicaltrials.gov (NCT0176146). A total of 546 patients were recruited between February 2013 and January 2018 with 182, 181, and 183 patients in the S-1, SOX, and SOXRT arms, respectively. Median follow-up period was 47 months, with 178 DFS events observed. Estimated 3-year DFS rates were 64.8%, 74.3%, and 72.8% in the S-1, SOX, and SOXRT arms, respectively. HR for DFS in the control arm (S-1) was shorter than that in the SOX and SOXRT arms: S-1 versus SOX, 0.692 (P = 0.042) and S-1 versus SOXRT, 0.724 (P = 0.074). No difference in DFS was found between SOX and SOXRT (HR 0.971; P = 0.879). Adverse events were as anticipated in each arm, and were generally well-tolerated and manageable. In patients with curatively D2-resected, stage II/III, node-positive GC, adjuvant SOX or SOXRT was effective in prolonging DFS, when compared with S-1 monotherapy. The addition of radiotherapy to SOX did not significantly reduce the rate of recurrence after D2 gastrectomy." @default.
• W3109883399 created "2020-12-07" @default.
• W3109883399 creator A5008976057 @default.
• W3109883399 creator A5011928803 @default.
• W3109883399 creator A5013311116 @default.
• W3109883399 creator A5015242661 @default.
• W3109883399 creator A5015598872 @default.
• W3109883399 creator A5017366532 @default.
• W3109883399 creator A5019305076 @default.
• W3109883399 creator A5027602837 @default.
• W3109883399 creator A5028131174 @default.
• W3109883399 creator A5032561728 @default.
• W3109883399 creator A5038001843 @default.
• W3109883399 creator A5043984377 @default.
• W3109883399 creator A5048832044 @default.
• W3109883399 creator A5055097851 @default.
• W3109883399 creator A5059143364 @default.
• W3109883399 creator A5060913021 @default.
• W3109883399 creator A5062162923 @default.
• W3109883399 creator A5065244228 @default.
• W3109883399 creator A5072048377 @default.
• W3109883399 creator A5075932421 @default.
• W3109883399 creator A5078806904 @default.
• W3109883399 creator A5084099617 @default.
• W3109883399 creator A5084870834 @default.
• W3109883399 date "2021-03-01" @default.
• W3109883399 modified "2023-10-17" @default.
• W3109883399 title "A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial☆" @default.
• W3109883399 cites W2012579585 @default.
• W3109883399 cites W2026986976 @default.
• W3109883399 cites W2049397238 @default.
• W3109883399 cites W2105064110 @default.
• W3109883399 cites W2113947048 @default.
• W3109883399 cites W2137991416 @default.
• W3109883399 cites W2149895338 @default.
• W3109883399 cites W2165299947 @default.
• W3109883399 cites W2473846162 @default.
• W3109883399 cites W2763640718 @default.
• W3109883399 cites W2797145364 @default.
• W3109883399 cites W2883750142 @default.
• W3109883399 cites W2921935701 @default.
• W3109883399 doi "https://doi.org/10.1016/j.annonc.2020.11.017" @default.
• W3109883399 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33278599" @default.
• W3109883399 hasPublicationYear "2021" @default.
• W3109883399 type Work @default.
• W3109883399 sameAs 3109883399 @default.
• W3109883399 citedByCount "127" @default.
• W3109883399 countsByYear W31098833992021 @default.
• W3109883399 countsByYear W31098833992022 @default.
• W3109883399 countsByYear W31098833992023 @default.
• W3109883399 crossrefType "journal-article" @default.
• W3109883399 hasAuthorship W3109883399A5008976057 @default.
• W3109883399 hasAuthorship W3109883399A5011928803 @default.
• W3109883399 hasAuthorship W3109883399A5013311116 @default.
• W3109883399 hasAuthorship W3109883399A5015242661 @default.
• W3109883399 hasAuthorship W3109883399A5015598872 @default.
• W3109883399 hasAuthorship W3109883399A5017366532 @default.
• W3109883399 hasAuthorship W3109883399A5019305076 @default.
• W3109883399 hasAuthorship W3109883399A5027602837 @default.
• W3109883399 hasAuthorship W3109883399A5028131174 @default.
• W3109883399 hasAuthorship W3109883399A5032561728 @default.
• W3109883399 hasAuthorship W3109883399A5038001843 @default.
• W3109883399 hasAuthorship W3109883399A5043984377 @default.
• W3109883399 hasAuthorship W3109883399A5048832044 @default.
• W3109883399 hasAuthorship W3109883399A5055097851 @default.
• W3109883399 hasAuthorship W3109883399A5059143364 @default.
• W3109883399 hasAuthorship W3109883399A5060913021 @default.
• W3109883399 hasAuthorship W3109883399A5062162923 @default.
• W3109883399 hasAuthorship W3109883399A5065244228 @default.
• W3109883399 hasAuthorship W3109883399A5072048377 @default.
• W3109883399 hasAuthorship W3109883399A5075932421 @default.
• W3109883399 hasAuthorship W3109883399A5078806904 @default.
• W3109883399 hasAuthorship W3109883399A5084099617 @default.
• W3109883399 hasAuthorship W3109883399A5084870834 @default.
• W3109883399 hasBestOaLocation W31098833991 @default.
• W3109883399 hasConcept C121608353 @default.
• W3109883399 hasConcept C126322002 @default.
• W3109883399 hasConcept C141071460 @default.
• W3109883399 hasConcept C143998085 @default.
• W3109883399 hasConcept C168563851 @default.
• W3109883399 hasConcept C203092338 @default.
• W3109883399 hasConcept C204243189 @default.
• W3109883399 hasConcept C207103383 @default.
• W3109883399 hasConcept C2776694085 @default.
• W3109883399 hasConcept C2778424827 @default.
• W3109883399 hasConcept C2780470880 @default.
• W3109883399 hasConcept C2780962732 @default.
• W3109883399 hasConcept C44249647 @default.
• W3109883399 hasConcept C526805850 @default.
• W3109883399 hasConcept C71924100 @default.
• W3109883399 hasConcept C90924648 @default.
• W3109883399 hasConceptScore W3109883399C121608353 @default.
• W3109883399 hasConceptScore W3109883399C126322002 @default.
• W3109883399 hasConceptScore W3109883399C141071460 @default.
• W3109883399 hasConceptScore W3109883399C143998085 @default.
• W3109883399 hasConceptScore W3109883399C168563851 @default.
• W3109883399 hasConceptScore W3109883399C203092338 @default.
• W3109883399 hasConceptScore W3109883399C204243189 @default.

• next